You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Small Molecule targeting of NADPH oxidase in neutrophils

    SBC: P2D, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Contractile Hydrogel Dressing for Primary Wound Closure

    SBC: LYNNTECH INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Acute and chronic wounds such as diabetic foot ulcers represent a major area of medical concern. With roughly 27 million patients suffering from these types of partial thickness wounds, representing substantial billions in medical expenses, a means to rapidly close such acute and chronic wounds with minimal medical staff involvement would be a major new bre ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS

    SBC: XFIBRA, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearance by apoptosis may allow recovery from liver injury andreversal of liver fibrosis. There is full agreement among liver fibrosis experts that inhibiting o reversing HS activation (the therapeutic targ ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. APPSPIRE: expanding the reach of an innovative tobacco control program for youth

    SBC: Radiant Creative Group, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Mobile phone technology offers a variety of opportunities for innovative approaches to health communication and intervention. These opportunities have been amplified by the emergence of next-generation smartphone devices that are capable of rich multimedia and sophisticated interactivity. Smartphone-based programs can be integrated seamlessly into a user's ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Kinetic image cytometry assays for neuronal activity/toxicity

    SBC: VALA SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The proposed project is a Phase I STTR collaboration between Vala Sciences Inc, a small business that specializes in the development of cell-based high content/high throughput assays, and the Sanford Burnham Medical Research Institute, a worldwide leader in biomedical research. The project will develop an assay (Kinetic Image Cytometer-Neuron, or KIC-Neuron) to ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma

    SBC: Oncosynergy, Inc.            Topic: 102

    PROJECT SUMMARY More thanpatients are diagnosed each year with glioblastomathe most common primary brain tumorCurrent treatments are inadequate and there have been no major therapeutic breakthroughs in decadesHencethere is an urgent need to develop novel strategies to address this devastating diseaseHoweverdevelopment of an effective treatment for glioblastoma is severely hampered bythe blood brai ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid Development of a Highly Specific Dengue Diagnostic Test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Brachytherapy Agent for GBM

    SBC: APPLIED INTEGRIN SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Despite advances in surgery, chemotherapy, and radiation therapy, the average life span of a patient with glioblastoma multiforme (GBM) is about 15-months from time of diagnosis. Integrins are heterodimeric receptors found on the surface of GBM cells and angiogenic vasculature; they facilitate invasion into adjacent tissue. Normal brain tissue does not display ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government